Is Wegovy as Effective as Ozempic for Weight Loss?

You've heard Ozempic works — so why can't you just get that instead?

It's one of the most common questions people bring to our prescribers, and honestly it makes sense. Ozempic became a cultural shorthand for GLP-1 weight-loss treatment long before Wegovy dominated the headlines, and the two names get used interchangeably online. But in UK law they are distinct products with distinct licences. Ozempic's maximum dose is 2 mg weekly, approved to improve blood-sugar control in adults with type 2 diabetes. Wegovy goes up to 2.4 mg (and now, with the MHRA's approval in April 2026 of a dedicated single-dose pen, up to 7.2 mg), specifically for weight management.

That dose gap is not trivial. The STEP 1 clinical trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. Ozempic's 2 mg ceiling was never studied at the same scale for weight loss outcomes. If a clinician prescribed Ozempic off-label for weight loss, they would be operating outside its licensed indication, which carries its own clinical and regulatory implications. A regulated service prescribing within licensed indications will offer you Wegovy, not Ozempic. You can read more about how Wegovy and Ozempic differ if you'd like the full side-by-side breakdown.

What Wegovy is actually licensed for in the UK, and where Ozempic fits

The NHS medicines page for semaglutide is clear: both Wegovy and Ozempic contain semaglutide, but they are listed as separate medicines with different approved uses. Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or sleep apnoea. Ozempic is a diabetes treatment. It is not assessed or approved by the MHRA as a weight-loss medicine.

NICE's appraisal of semaglutide (TA875) covers Wegovy specifically, not Ozempic, and frames its NHS recommendation around specialist weight management services, and you can find the Wegovy BNF entry a useful reference point for understanding how the medicine is classified and dosed within that framework. For people accessing treatment privately, the same principle applies: the prescription should name the product that carries the weight-management licence. If you're curious about whether Wegovy would be appropriate for your situation, our Wegovy overview covers eligibility, how the dose titration works, and what to expect.

It's also worth knowing that Rybelsus (yet another semaglutide product) is an oral tablet for type 2 diabetes, not weight loss. The oral weight-loss tablet is Wegovy tablets, approved by the MHRA in June 2026. Different product, different indication, same naming confusion. The page on semaglutide explained unpicks all of this if you need a clearer map.

How Wegovy compares to Mounjaro, the option many people don't consider

Once you've landed on Wegovy as the correct licensed comparison point rather than Ozempic, it's worth knowing where Wegovy sits relative to the other weight-management injection available in the UK. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, meaning it activates two appetite-related pathways rather than one. In the SURMOUNT-5 trial, involving 751 adults with obesity and no diabetes, tirzepatide produced a greater average reduction in body weight than semaglutide 2.4 mg over 72 weeks. NICE acknowledged these results in its appraisal of tirzepatide (TA1026), published in December 2024.

That said, Wegovy at 7.2 mg narrows the gap considerably, and the right medicine depends on your health history, any other medicines you take, and what a prescriber concludes after a proper assessment. Neither option is better in the abstract. Our page comparing weight-loss drugs including Ozempic and Wegovy walks through these distinctions, and if you want to understand the cost picture before starting anything, the weight-loss treatment overview gives an honest summary of what private treatment typically involves. When you're ready to check whether you'd be eligible, you can check your eligibility with our prescribers.

What both medicines share, and why that matters for safety

GLP-1 receptor agonists as a class slow gastric emptying and reduce appetite through gut-hormone pathways. Whether the product is Wegovy or Ozempic, the side-effect profile is similar: nausea, digestive discomfort, and occasionally headaches or fatigue, most noticeable at the start of treatment or after a dose increase, and usually settling over time. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but serious risk across this class, severe, persistent stomach pain reaching the back warrants urgent medical attention.

For tirzepatide specifically, women using oral contraceptives should use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced. NHS England advises the same consideration for transdermal HRT. These are the kinds of details that only surface when a real clinician reviews your full medication history, which is precisely why these medicines are prescription-only. A fuller look at semaglutide and weight loss covers the safety picture in more depth, including when to seek help. If you have specific questions about how treatment fits your circumstances, our frequently asked questions may help, or you can reach us directly through the contact page.